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Abstract Primary mediastinal B-cell lymphoma (PMBCL) is
a relatively rare lymphoma subtype affecting mainly young
adults. Its molecular signature and clinical features resemble
classical Hodgkin lymphoma. The optimal chemotherapy for
this lymphoma subtype has not been established. The addition
of rituximab to anthracycline based chemotherapy improved
response rates and survival. Many centers use R-CHOP as
standard treatment, but the role of the intensified regimens and
consolidation radiotherapy has to be clarified. Recent data
coming from retrospective analyses and an ongoing prospec-
tive study addressing the problem of consolidation radiother-
apy will help to better identify risk groups and apply risk-
adapted and effective treatment strategies. The latest research
has helped to understand molecular mechanisms of PMBCL
pathogenesis and indicated targets of directed therapy for the
future.
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Introduction
Primary mediastinal B-cell lymphoma (PMBCL) belongs to
the group of aggressive diffuse large B-cell lymphomas. The
current WHO 2008 classification distinguished this lympho-
ma as a separate entity due to its specific clinical and patho-
logical features [1]. Gene expression profile studies showed
that it shares common features with classical Hodgkin lym-
phoma (cHL) [20, 21]. Treatment outcomes in the pre-
rituximab era were not satisfactory with high relapse rates.
Adding rituximab to anthracycline based regimens improved
patient prognosis, and R-CHOP has been widely adopted as
the standard treatment. However, there are still unresolved
questions in the therapy of PMBCL. There are questions such
as, is R-CHOP an optimal regimen for all patients? Historical
data indicated superiority of more intense chemotherapy reg-
imens, but they have not been compared to R-CHOP directly,
and there is no consensus which group of patients would
benefit from intensified regimens. Also, there is no convincing
data supporting the use of radiotherapy. Retrospective studies
generally did not show survival benefit, and late toxicities like
cardiotoxicity and secondary cancers cannot be neglected.
However, the questions if radiotherapy can be safely omitted
and in which patient group it can be omitted, so far have not
been answered. Relatively low patient numbers are the main
obstacle in conducting randomized prospective trials, so ther-
apeutic decisions have been based mainly on retrospective
studies.
Epidemiology
PMBCL constitutes approximately 2 % to 4 % of all non-
Hodgkin lymphomas (around 6 % of diffuse large B-cell
lymphomas (DLBCL)). This disease affects mainly young
adults (median age of 35), predominantly women (female/
male ratio 1.7-2/1) [2]. There are also cases of PMBCL
among children and adolescents [3]. No risk factors for
this type of lymphoma have been identified; however, a
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familial case of PMBCL has been described in Finland, prob-
ably related to the 5533C>A mutation in the MLL gene. [4].
Clinical Presentation
PMBCL typically presents as a large, fast-growing tumor with
invasion usually limited to the anterior-upper mediastinum
although it tends to infiltrate adjacent thoracic structures like
the chest wall, pleura, lungs, pericardium, and heart causing
pleural/pericardial effusion in approximately 30–50 % of
cases. The disease is mainly locally advanced. Eighty percent
of patients have clinical stage I and II and 75 % of them have
bulky disease with a tumor mass exceeding 10 cm. Enlarged
lymph nodes localized outside the mediastinum are rarely
found. Bone marrow infiltration is seen in few cases [5, 6,
7••, 8]. Recurrent disease tends to spread to distant extranodal
organs like the kidneys, adrenal glands, liver, central nervous
system, and less frequently to the lymph nodes. Typical symp-
toms such as cough, tachypnoe, vein thrombosis, chest pain,
or dysphagia are related to the tumor mass infiltration or
compression, with a history of complaints for usually less
than three months. Approximately half of the patients present
with upper vena cava syndrome. Systemic symptoms, mainly
weight loss and fever, are relatively rare and they affect less
than 20 % of patients [2].
Pathology
PMBCL arises in the thymus from a so-called thymic B-cell
originating either from a germinal center or a nongerminal
center but with an expression of an activation induced cytidine
deaminase (AID) gene. Cells are heterogenous, medium-sized
to large-sized, with a pale, abundant cytoplasm. Their nuclei
also show a degree of heterogeneity. They could be oval,
irregular, pleomorphic like Reed-Sternberg cells or
multilobated like in DLBCL. Characteristic feature of
PMBCL is sclerosis dividing tumor tissue into compartments.
Collagen bands are fine and not as broad as in cHL nodular
sclerosis (NS) types. Immunophenotyping of tumor cells
shows positive surface staining for pan-B cell antigens:
CD19, CD20, CD22, also in a majority of cases for CD23,
CD45 and MAL [1, 9, 10]. The last, associated with the
specific population of B lymphocytes, thymic medullary B-
cells, is expressed in 70 % of PMBCL, and it might be useful
in differentiating PMBCL from DLBCL (expression only in
3 %) [11, 12]. CD30, being an attractive therapy target in
Hodgkin lymphoma or anaplastic lymphoma, is also positive
in most of the PMBCL cases but its expression is usually
weaker than in the mentioned lymphoma types. PMBCL cells
are usually CD10(-) and CD15(-). They also typically lack
surface immunoglobulin (sIg) and, what is characteristic for
this lymphoma type, only one component of the B-cell recep-
tor is present, namely CD79a [10]. Another significant feature
of PMBCL cells is decreased or, in some cases, absent ex-
pression of human leukocyte antigen class I and II (HLA)
correlated to worse outcome [13]. MUM1/IRF4 expression
has been found to be present in 45 % of the cells and is also
associated with inferior survival [14]. Staining for transcrip-
tional factors PU.1, OCT2, PAX5, and BOB1 is often positive
[10]. BCL2 and BCL6 are positive by immunohistochemistry
in a majority of cases [10, 15, 16]. Knowledge of the charac-
teristic immunophenotype of PMBCL cells is necessary in
differential diagnosis. A decision tree for discriminating be-
tween PMBCL and cHL has been proposed by Hoeller S.
et al., using mainly three markers: CD79a or alternatively
BOB1with combination with cyclin E. Applying this diagram
enables classification correctly for 97-98 % of the patients to
either PMBCL or cHL groups [17].
Molecular Pathology
Somatic hypermutations of immunoglobulin genes and BCL6
in PMBCL were found in some studies and they confirmed
germinal (post-germinal) center origin of the malignant cells
[18]. Notably, the mutated region in BCL6 gene differs from
DLBCL and follicular lymphoma [19]. In 2003 two indepen-
dent studies were published, indicating that PMBCL has a
unique molecular transcriptional pattern, distinct from
DLBCL but having common features with cHL [20, 21]. Gene
expression profiling (GEP) showed that over one-third of the
genes overexpressed in PMBCL are also strongly expressed in
HL cells. These genes are mostly related to the important
signaling pathways of NFκB and JAK-STAT [21]. Dysregu-
lation of these pathways contributes to the malignant pheno-
type of PMBCL leading to the inhibition of apoptosis and
increased proliferation [22••]. NFκB is one of the most im-
portant transcription factors in the cell, responsible for prolif-
eration and survival and constitutive activation of NFκB is
typical for PMBCL [23]. This is achieved via different mech-
anisms such as overexpression of the tumor necrosis factor
(TNF) receptor superfamily activating this pathway and over-
expression of NFκB complex members [22••]. A20 protein is
a negative regulator of IκB and NFκB, and a gene encoding
this protein, TNFAIP3, is mutated in 36% of cases resulting in
constitutive activation of NFκB [24]. Nuclear localisation of
REL, one of the NFκB complex proteins, is related to the
activation of the NFκB pathway. Genomic gains and amplifi-
cations of the REL protooncogene locus on the short arm of
chromosome 2p are present in over half of the PMBCL cases
and associated with the nuclear position of REL [25, 26].
JAK-STAT is another major pathway responsible for the reg-
ulation of cell proliferation. The JAK-STAT signaling cascade
is activated by interleukin (IL) receptors, mainly IL-4 and IL-
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13, and aberrations have been found on different levels of this
pathway, starting from an enhanced IL-13 receptor expression
[20, 21]. Genomic gains of distant regions of chromosome 9 -
9p24.1 containing a locus for JAK2 have been found in
approximately 63% of PMBCL cases, and they correlate with
an increased JAK2 mRNA and protein levels [27•], leading to
JAK-STAT cascade activation and cell proliferation. Amplifi-
cation of 9p24.1 and overexpression of JAK2 is also associ-
ated with an upregulation of an immunoregulatory pro-
grammed death (PD)-1 ligand resulting in the exhaustion of
T lymphocytes [27•]. One of the key proteins in the JAK-
STAT pathway is STAT6 protein and constitutive activation of
STAT6 is typical for PMBCL [28]. Moreover, in 36 % of
PMBCL somatic mutations in STAT6 DNA-binding domain
cases have been identified, confirming the role of
dysregulations of JAK-STAT in PMBCL pathogenesis [29].
Genes coding for a suppressor of cytokine signaling 1 (SOCS-
1), a negative regulator of this pathway, have been found to be
mutated in some PMBCL patient cases and in mediastinal B-
cell lines leading to delayed degradation and prolonged phos-
phorylation of JAK2 [30]. PTNP1 being another negative
regulator of JAK-STAT has been recently described to be
mutated in 22 % of PMBCL cases, also resulting in increased
phosphorylation of JAK2, although only a trend towards
inferior progression-free survival in mutated cases was noted
[31].
Another pathological mechanism giving survival advan-
tage is correlated to tumor microenvironment reactions en-
abling the tumor to escape from immunosurveillance. One of
them is a decreased expression of major histocompatibility
complex (MHC) class II genes and proteins in PMBCL as
shown by gene expression profiling and immunohistochem-
istry studies, correlating with reduced cytotoxic CD8 T cell
numbers and inferior survival [13, 32]. MHC expression is
regulated by the MHC class II transactivator CIITA. Genomic
breaks in CIITAwere found to be present in 38 % of PMBCL,
and they were associated with lower levels of MHC class II
expression, and a significantly lower patient survival rate [33].
Genomic rearrangements in CIITA also have an impact on the
expression of programmed cell death ligands-1 – PD-1 ligands
on the surface of PMBCL cells (PD-L2 - CD273 and PD-L1-
CD274). These molecules are involved in costimulatory sig-
nal transduction between malignant cells and PD-1 receptor
on T cells, in addition to T cell receptor (TCR) signaling,
modulating T cell activity. Overexpression of PD-L2 and
PD-L1 leads to an exhaustion of infiltrating T cells and the
tumor’s escape from immunosurveillance [33]. Genes
encoding PD-L1 and PD-L2 are located in the 9p24.1 region,
similarly to JAK2 [27•]. Recently, genomic rearrangements
involving PD-L locus have been described in 20 % PMBCL,
including break-apart, amplifications, and gains, and they
were associated with PD-L protein overexpression. It was
noteworthy that, although no survival correlation was
established between rearranged and nonrearranged cases, the
PD-L levels in PMBCL cells were higher than in the normal
control, indicating another regulation pathway of PD-L ex-
pression [34]. Enhanced expression of PD-L1 on PMBCL and
on tumor associated macrophages was also confirmed by the
immunohistochemistry method in 71 % malignant cells [35•].
The results of cited studies shed light on the biology of
PMBCL and some of the dysregulated molecular mechanisms
described above will become an attractive therapy target in the
future. Preclinical studies show that selective inhibition of
JAK2 with fedratinib reduced phosphorylation of JAK2 and
other proteins from the STAT family in cHL and PMBCL cell
lines. It also inhibited the expression of PD-L1. In murine
models inhibition of JAK2 significantly decreased tumor
growth and prolonged survival, which was correlated with
reduced STAT3 expression [36••]. PD-L1 has already become
the subject of clinical trials in many cancers giving response
rates in 20-25 % of patients [37] and seems to be also a natural
therapy target in lymphomas overexpressing PD-L.
Diagnosis and Differential Diagnosis
Typical localization of PMBCL confined to mediastinum
without the involvement of peripheral lymph nodes requires
more invasive diagnostic procedures. Mediastinoscopy, ante-
rior mediastinotomy, or percutaneous CT-guided core needle
biopsies, are usually performed [2, 15]. Representative and
relatively extensive tissue samples should be taken, as the
cells can be damaged during the biopsy, which can make
diagnosis more difficult to establish.
Differential diagnosis of PMBCL includes other types of
lymphomas with mediastinal localization [9]:
– “gray zone” lymphoma - B-cell lymphoma, unclassifi-
able, with features intermediate between diffuse large B-
cell lymphoma and classical Hodgkin lymphoma [38],
– composite lymphoma consisting of two types of lympho-
ma: PMBCL and a cHL
– mediastinal sequential lymphomas (i.e., PMBCL relaps-
ing as HL)
– diffuse large B-cell lymphoma with anterior mediastinum
involvement
– cHL NS type [38]
– T-cell lymphoblastic lymphoma
– Thymoma
– Germ cell tumors
– Metastatic carcinomas
Diagnosis is made on the basis of histopathological exam-
ination with mandatory immunohistochemical staining and
typical clinical presentation.
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Diagnostic procedures performed to assess clinical stage
are typical and include physical examination, whole-body
computer tomography, bone marrow biopsy, whole blood
count, and blood biochemistry. Elevated LDH is found in
70-80 % of cases, and it can often be the only laboratory
abnormality [6, 8]. β2-microglobulin is usually within the
normal range [39]. PMBCL belongs to FDG-avid lympho-
mas, so PET/CT has been incorporated into the diagnostic
procedures carried out before and at the end of therapy (EOT)
[40]. Clinical stage is assessed using the Ann Arbor staging
system, and, as mentioned above, about 75 % of patients have
clinical stage (CS) I or II [5, 6, 7••, 8].
Prognostic Factors
For the assessment of risk category, a standard international
prognostic index (IPI) is used. However, its role in PMBCL is
limited due to the fact that two out of five risk factors deter-
mining patients’ survival are generally not present: age above
60 and CS III or IV [5, 6, 7••, 8]. Another reason for conflicting
results of using IPI for assessing patient risk is the lack of
consistency in evaluating the stage of the disease. Mediastinal
tumor infiltrating per continuum/extension other thoracic struc-
tures can be described by a treating physician as stage IIE or
stage IV. This may lead to discrepancies in evaluating the role
of IPI in PMBCL in retrospective analyses published by differ-
ent centers. In the authors’ opinion as described by
Vassilakopoulos et al. [41•], CS IV should be confined to
lymphoma with extensive dissemination to extranodal organs,
whereas a tumor infiltrating to a limited degree adjacent tho-
racic structures such as pleura, pericardium, thoracic wall or
lungs should be assessed as CS IIE. In the retrospective analysis
from 2012, age-adjusted IPI (aaIPI) in a multivariate analysis
failed to be of prognostic significance [41•]. This was similar to
an earlier series of 141 patients fromMemorial Sloan-Kettering
Cancer Center (MSKCC) [8]. In various published series of
PMBCL patients, other negative prognostic factors for survival
were described: age over 40 years of age, CS III and IV, bulky
disease, male sex, poor performance status (PS), and LDH>2 x
UNL [5, 6], but their prognostic power has not been validated
in large, prospective studies in the rituximab era. However, IPI
proved to be a significant factor for survival in R-CHOP-treated
patients in a recent retrospective study by a Japanese multicen-
ter study group including 345 patients (187 of them treated with
the R-CHOP regimen) [7••]. Multivariate analysis showed a
pleural/pericardial effusion to be another adverse factor for PFS
and a novel prognostic model for PMBCL (PMBL prognostic
index – PMBIPI) was designed, including two factors:
high/intermediate-risk and high-risk IPI and the presence of a
pleural/pericardial effusion. Patients in a low-risk group (0
factors) had a favorable overall survival (OS) of 97 % and
progression-free survival (PFS) 89 % at four years, whereas
patients with two adverse risk factors had a statistically inferior
4-year OS and PFS of 72 % (P=0.001) and 44 % (P<0.001).
As the authors stated, this novel prognostic index needs to be
evaluated in prospective studies [7••].
First-Line Therapy
Initial treatment is critical in the management of PMBCL since
outcomes of second and further therapy lines in relapsed/
progressive disease are unsatisfactory [6, 42, 43]. R-CHOP is
used in many centers world-wide but there are some reports on
the better efficacy of more intense chemotherapy regimens (so-
called third-generation) with a higher cytostatics dose/density.
However, these analyses are mainly retrospective and based on
a small number of patients. The role of consolidation radiother-
apy in the rituximab era and also in conjunction with third-
generation chemotherapy also needs to be determined.
Historically, before the rituximab era, PMBCL patients, like
in DLBCL, were treated with CHOP, usually with consolidation
radiotherapy, achieving a complete remission (CR) rate of 48-
70 % and a long-term overall survival of 33-65 % [5, 8, 44]
(Tables 1 and 2). A MInT study comparing CHOP to R-CHOP
is one of few prospective trials recruiting PMBCL patients, who
constituted 11 % (n=87) of all 824 DLBCL patients [45••]. The
studywas limited to young (age<60), low-risk patients, with CS
II-IVor I bulky and with IPI ≤1. The analysis showed that in the
PMBCL sub-group, the addition of rituximab to six cycles of
CHOP-like therapy [mainly CHOP-21 (50 %) and CHOEP-21
(49.5 %)] significantly increases CR rates (84 % vs 50 %; P=
0.03), lowers progression rates (2.5 % vs 24 %; P=0.006),
prolongs three year event-free survival (3-year EFS) - 78 % vs
52 %; P=0,012 and 3 year-OS (88.5 % vs 78.2 %; P=0.158).
The difference in OS was not statistically significant for the
PMBCL group in contrast to DLBCL (probably due to the
smaller number of patients). In a multivariate analysis therapy
containing rituximab and the absence of bulky disease were
significant positive prognostic factors for OS, EFS, and overall
response rates (ORR). The results of the MInT study, clearly
showed that, in low-risk PMBCL, adding rituximab to CHOP
improves treatment outcome, mainly by decreasing the progres-
sion rate, which established R-CHOP regimen as a standard of
care in many centers. Many retrospective reports comparing R-
CHOP with CHOP confirmed good outcomes in R-CHOP
treated patients yielding 5-year PFS 68 – 77 % and 5-year OS
79-90 %; some of them including a relatively high number of
patients (Table 2) [7••, 41•].
Despite the improvement of treatment outcomes with the
introduction of rituximab, there is a subgroup of patients re-
lapsing on primary R-CHOP chemotherapy. In the cited paper
by Vassilakopulous, patients with aaIPI≥2 had a worse survival
of 5-year FFP 63 % and 5-year OS 75% [41•]. Similarly, in the
abovementionedmulticenter analysis from Japan, patients with
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two adverse risk factors had a statistically inferior 4-year PFS
and OS of 44 % and 72 % [7••]. Another group reported on the
high rate of treatment failure in 63 R-CHOP patients, including
33 % with high/intermediate- and high-risk IPI [46•]. 5-year
PFS was 68 % and 5-year OS was 79 % for the whole
population; however, 21 % of patients had primary refractory
disease or relapsed early (8 %) and 63 % of them died of
lymphoma progression. Adverse prognostic factors for treat-
ment failure were: age>60, numerous extranodal sites, CS>II
in multivariate analyses, and also aaIPI in a univariate analysis.
Limited efficacy of R-CHOP in poor risk patients has
prompted some groups to use more intense chemotherapy regi-
mens. Such treatment approaches were applied in the pre-
rituximab era, resulting in significantly better outcomes as com-
pared to standard CHOP. One of the largest studies was a
multinational retrospective analysis including 426 patients,
which proved the superiority of the third-generation regimens
(mainly MACOP-B and VACOP-B) over CHOP and CHOP-
like [5]. Similar results were reported by other study groups [8,
42, 47], (Table 1). There is no certainty if adding rituximab to the
third-generation chemotherapy brings any clinical benefit. Com-
paring the retrospective data of two groups of patients, that is,
those treated with MACOP-B/VACOP-B and those with the
same regimen but with the addition of rituximab, showed no
statistical difference in relapse free survival and CR rates [48]. A
more important problem that has not been addressed in random-
ized trials is the evaluation of third-generation regimens in the
rituximab era by comparing them to standard R-CHOP chemo-
therapy. However, some papers on that topic have been pub-
lished. They are mainly retrospective analyses or single-arm
phase II studies assessing treatment outcomes with the use of
more intense regimens. In 2013 the results of a prospective,
phase II trial carried out in the National Cancer Institute (NCI)
were published. Fifty-one patients with PMBCL were treated
with 6-8 cycles of rituximab dose adjusted EPOCH (R-DA-
EPOCH) chemotherapy without consolidation radiotherapy. It
was given to only 4% of patients who did not achieve CR [49••].
Adverse prognostic factors were frequently present in this pop-
ulation. Five-year EFSwas 93% and 5-year OSwas 97%with a
median follow-up of 63 months. Toxicity was mainly hemato-
logical with neutropenia grade 4 occurring in 50 % of cycles,
thrombocytopenia grade 4 in 6 %, and neutropenic fever in
13 % cycles. The results were compared to the historical cohort
of DA-EPOCH-treated patients and, in contrast to Zinzani’s
study, significant survival benefit for the rituximab-containing
regimen was proved. Another intensified chemotherapy regimen
is GMALL B-ALL/NHL 2002, based on pediatric ALL proto-
cols, created by the German Multicenter Adult ALL Study
Group (GMALL). It is an intense, multidrug regimen consisting
of six courses, each containing rituximab and methotrexate at a
dose of 1.5 g/m2, with intrathecal prophylaxis. At first, radiother-
apy was obligatory but after protocol amendment it was left to
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assessment. The first results on 44 patients treated (without
rituximab but with consolidation radiotherapy) in a few German
centers were published in 2002 and they showedORR exceeding
90%, PFS – 85% andOS – 82% [50]. In 2011 the results of the
next cohort of 15 patients treated with rituximab confirmed the
high efficacy of this regimen yielding 5-year PFS 93.3 %, and 5-
year OS 100 % [51•]. Our own experience in applying this
intense chemotherapy regimen is also very encouraging. Since
2004 we have treated over 65 PMBCL patients including those
with negative prognostic factors. With a median follow-up of
41 months 5-year PFS was 92% and 5-year OSwas 93%.Most
of the patients received consolidation radiotherapy. Toxicity was
manageable and similar to previously published results: neutro-
penia 3 and 4 grade in 81% of all cycles, trombocytopenia grade
>2 in 58% of the cycles, neutropenic fever in 28% of the cycles,
and also mucositis was noted in 27 % of the cycles. A retrospec-
tive survey of 109 patients by the Polish Lymphoma Research
Group showed that patients treated with R-CHOP-21 had a
significantly higher risk of treatment failure as com-
pared to dose dense (R-CHOP-14) and dose intensified
(GMALL B-ALL/NHL 2002 and high-dose therapy con-
solidation) groups [52] (Fig. 1). Although intensified
regimens like R-DA-EPOCH and GMALL B-ALL/
NHL 2002 seem to improve survival, their superiority
over R-CHOP has not been proved in randomized trials
and this potential benefit must be balanced against sig-
nificant, albeit manageable, toxicity.
Evaluation of Response to Therapy – The Role of PET/CT
The most useful, although not ideal tool, for assessing re-
sponse to treatment is PET/CT [40]. Earlier CT was used but
its value was sometimes limited as in many cases residual
tumors were present after the treatment due to excessive
fibrosis, and distinguishing between active and non-active
mass was impossible. Published data show that PMBCL
PET/CT has high sensitivity and high negative predictive
value (NPV) but low specificity and positive predictive value
(PPV) [54•, 55]. In the NCI series, 18 out of 36 patients with
residual mass had positive PET but only three with SUV ≥5
had active disease [49••]. In an Italian cohort of 37 patients,
68 % had positive PET after R-chemotherapy but after radio-
therapy 85 % converted to CR [53]. Only patients with the
highest score of 5 progressed despite radiotherapy and their 2-
year OS was significantly worse (33 % vs 100 %). Another
important study recently published was IELSG-26 by the
International Extranodal Lymphoma Study Group [54•].
There were 115 patients assessed with PET/CT after
immunochemotherapy. Forty-seven percent achieved meta-
bolic CR (metCR) (18FDG uptake below mediastinal blood
pool, score 1 and 2) and had an excellent 5-year OS of 100 %
and PFS 98 %. Among 53 % PET-positive patients those with
score 4 and 5 (18FDG uptake above liver) had significantly
worse 5-year PFS (68 % vs 99 %) and OS (83 % vs 100 %)
than patients with score 1-3. None of the patients with score 3
(residual uptake) progressed/relapsed, but notably 89 % of
them received radiotherapy, so the rate of real false positive
results in this group is unknown. This study confirms good
prognosis of EOT-PET-negative patients and a high proportion
of positive EOT-PET in PMBCL, probably due to the inflam-
mation or thymic rebound contributing to relatively low PPVof
PET. Consistent with previous studies, patients with the highest
scores/18FDG uptakes are at the highest risk of progression/
relapse [49••, 53, 54•]. Data on the role of interim PET/CT is
rather scarce. In a study byMSKCC, interim PET did not prove
to be of prognostic value [56]. However, two recent reports
confirmed high NPV (86-100 %) and lower PPV (30-75 %) of
interim PET and in both studies patients with negative interim
PET achieved long-term remission [55, 57].
Fig. 1 Survival of PMBCL
patients treated with different
chemotherapy regimens –
retrospective analysis of the
Polish Lymphoma Research
Group. Treatment outcomes of
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The Role of Consolidation Radiotherapy
In the past, radiotherapywas an important part of the treatment
strategy, mainly due to the less effective chemotherapy in the
pre-rituximab era, but no clear survival benefit was proven.
Retrospective analysis of 426 patients showed that involved-
field radiotherapy (IFRTH) increased CR rates in both stan-
dard and intense chemotherapy groups. Eighty-one percent of
patients with PR converted to CR, however, no improvement
in survival was observed [5]. In another study, patients who
received radiotherapy had significantly longer EFS, regardless
of their chemotherapy regimen, with no difference in OS [42].
In a population based analysis from 2006, no difference in
PFS or OS between irradiated and nonirradiated patients treat-
ed with various chemotherapy regimens was observed [6].
Other studies with more intense treatment regimens showed
good results without IFRTH [8, 47]. With the advent of more
effective chemotherapy yielding high CR rates, the necessity
of conducting IFRTH has become a matter of debate. In the
cited NCI study, 9 6 % of patients treated with R-DA-EPOCH
were not irradiated and achieved 5-year OS of 97 % [49••].
The MSKCC group showed 3-year OS 88 % and 3-year PFS
78 % for 54 patients treated with R-CHOP/ICE without ra-
diotherapy [56]. A PET-guided strategy proposed by the Brit-
ish Columbia Cancer Agency indicated that the outcomes of
patients with negative EOT-PET, who did not receive IFRTH,
were similar to irradiated EOT-PET positive patients, suggest-
ing that achieving metabolic CR may reduce the need for
radiotherapy [58•]. Similar conclusions were drawn from the
retrospective analysis from Italy. Radiotherapywas given only
to PET-positive patients and there was no difference in disease
free survival between this group and the PET-negative nonir-
radiated group [59]. In a Japanese study, the outcomes of PET-
negative patients were similar, irrespective if they received
IFRTH or not [7••]. A newly launched IELSG-37 study will
probably give a definite answer to the question on the role of
consolidation radiotherapy in PMBCL. The study is powered
to determine noninferior outcome in patients not receiving
radiotherapy. Patients who achieve metCR after R-CHOR/R-
CHOP-like chemotherapy (R-CHOP-14/21, R-MACOP/B,
R-DA-EPOCH, R-ACVBP) will be randomized to mediasti-
nal radiotherapy of 30 Gy or to the observation arm. This
important trial will help to determine whether omitting
IFRTH, which allows sparing late toxicity in this young
patient population, is a safe strategy [www.clinicaltrials.gov;
NCT01599559].
Treatment of Relapsed/Refractory Disease. The Role
of Stem Cell Transplantation
In the pre-rituximab era, early progression was a relatively
frequent event and occurred in approximately 20 % of cases.
Immunochemotherapy significantly decreased this rate [45••]
but primary refractory or relapsed disease still remains a
problem, especially in the high-risk population. Relapses usu-
ally occur early, within 12-24 months, very rarely beyond two
years, typically affecting extranodal sites, including the central
nervous system (CNS). Earlier data on the risk of CNS re-
lapses indicated quite a high risk of CNS involvement at
relapse at up to 27 % [60], but recent publications do not
confirm these numbers. Isolated CNS relapse was described in
2 % of 100 R-CHOP +/- RTH-treated patients and in 4.4 % of
45 CHOP-treated patients [61]. A British Columbia study also
shows a low incidence of CNS relapse in similar patient
subgroups (2.1 % for R-CHOP vs 3.2 % for CHOP) [58•].
Treatment strategies for relapsed disease do not differ from
DLBCL salvage therapy including those not cross-resistant
agents and consolidation with high-dose therapy and stem cell
transplantation (SCT), mainly autologous, for fit patients;
however, the results are rather disappointing. A retrospective
survey from 2008, comparing 37 relapsed/refractory PMBCL
patients with 143 DLBCL patients, showed that in PMBCL
patients ORR to first-line salvage therapy was lower as com-
pared to DLBCL (25 % vs 48 %, P=0.01) and 2-year OS was
also inferior (15 % vs 34 %, P=0.018) [43]. More PMBCL
patients progressed after salvage therapy (61 % vs 35 %) and
fewer patients achieved remission and proceeded to autolo-
gous SCT. PMBCL patients with chemosensitive disease had
similar outcomes to DLBCL patients after autoSCT. Primary
refractory patients had the worst prognosis.
Autologous SCT is also used as a consolidation of the first
line therapy, especially in high-risk patients and in patients
who achieved only PR. In the GEL-TAMO experience, pa-
tient outcome depended mostly on the disease status before
autoSCT. Patients in CR had 4-year PFS and OS of 81 % and
84 %, patients in PR 56 % and 64 %, respectively [62].
Primary refractory patients had significantly inferior survival
with 4-year PFS of 16% and OS of 23%. Similar results were
reported by other groups [63]. In a retrospective analysis of
PLRG, no difference in survival was found between intensi-
fied GMALL B-ALL/NHL 2002 regimen and frontline treat-
ment with autoSCT after R-CHOP chemotherapy [52], simi-
larly to the IELSG cohort [5].
In summary, autoSCT remains a valid strategy in relapsed/
refractory disease; however, the main factor determining long-
term survival is achieving CR before the procedure. Since
rituximab based chemotherapy and third-generation regimens
improved survival in PMBCL, the role of frontline autoSCT is
now debatable.
Conclusions
PMBCL is a distinct clinicopathological entity and needs to be
thoroughly differentiated with other lymphoma types, especially
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medDLBCL, cHL and gray zone lymphoma. Since the inci-
dence of PMBCL is not high, the optimal treatment choice is
based mainly on retrospective data or few prospective studies
without control groups or including low patient numbers. There
is a strong rationale supporting the use of rituximab based
chemotherapy coming from a subgroup analysis of a prospective
MInT trial and from numerous retrospective analyses with his-
torical control groups. The results unequivocally show that the
addition of rituximab to a standard anthracycline containing
regimen CHOP/CHOP-like improves response rates, survival,
reduces progression rates, and, therefore, R-CHOP has become a
new standard of care in many centers. Despite this improvement,
the risk of disease progression/relapse is still not negligible. It is
up to 20 %, especially in high-risk groups, and intensified
regimens are being developed and used. These regimens seem
to bring clinical benefits in survival, allowing in some cases to
omit IFRTH, but at the cost of significantly increased toxicity.
More importantly, they have not been compared to R-CHOP in a
randomized study. As the substantial part of patients achieve
long-term survival with R-CHOP (+/- RTH), the main problem
is to identify a group of patients who would really benefit from
the third-generation regimes and for whom this excessive,
though short-term toxicity would be clinically justifiable. The
role of radiotherapy in the era of more effective
immunochemotherapy remains a matter of debate. It un-
doubtedly improves the quality of response, but there is
no consensus in which clinical settings radiotherapy can
be safely omitted. A PET-guided approach based on
data from retrospective surveys seems to be the most
rational one, and the ongoing prospective randomized
study will hopefully answer this important clinical ques-
tion. Response to standard salvage therapy in refractory/
relapsed disease is lower than in DLBCL and new
treatment strategies are needed. Recent research has
brought a new insight into molecular mechanisms con-
tributing to the malignant phenotype of PMBCL and
this could direct development of targeted therapies.
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